Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364351 · ClinicalTrials.gov registry record · Phase 3
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,574
- Enrollment target
NCT00364351: Completed Phase 3 study, sponsored by Genzyme, a Sanofi Company.
NCT00364351 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 1,574 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (104% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00364351, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,574 participants
- Enrollment target
Study Summary
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
Primary Outcome
Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable Response Evaluation Criteria In Solid Tumors (RECIST) assessment. Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appeara
Interventions
- DRUG Erlotinib
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,574 participants |
| Start Date | 2006-08 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
What the finished NCT00364351 record still lists
NCT00364351 is an interventional study that assigns participants to a tested intervention. Its 1,574 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (104% higher).
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00364351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00364351 about?
NCT00364351 is a clinical study titled "Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy". To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
What is the current status of trial NCT00364351?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,574 participants. The study started on 2006-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00364351?
The interventions under investigation include: Erlotinib (DRUG), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT00364351?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00364351's enrollment target sits among peer trials
1,574 149th of 2000 higher than 1,852 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445946 · 1,572 participants · Phase 4
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
- NCT06034080 · 1,566 participants · NA
Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections
- NCT06881069 · 1,560 participants · NA
Reach Through Equitable Implementation in Utah
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia